Ex vivo culture of human biopsies with idenTx: leveraging the STING pathway to complement NK-cell therapy
In a recent publication in Cancer Immunology Research, a team led by scientists at Dana-Farber Cancer Institute and Brigham and Women’s Hospital used AIM Biotech’s idenTx drug discovery platform to demonstrate the therapeutic potential of STING (stimulator of...
AIM Biotech partners with Nikon to provide organ-on-a-chip imaging and analysis contract services for drug discovery
Nikon Corporation announced on Wednesday that AIM Biotech is one of the select organ-on-a-chip (OOAC) providers to support Nikon’s expanding global contract research services for drug discovery. This partnership is a result of collaborative efforts between Nikon and...
How AIM Biotech is automating organ-on-a-chip drug discovery
AIM Biotech is using Opentron’s lab robot to implement automated drug discovery on in vitro platforms that provide more predictive data and higher throughput When the scientists at AIM Biotech developed our idenTx organ-on-a-chip (OOAC) platform for human...
Understanding PD-L1 expression in breast cancer with the idenTx chip
In this last article of the immune checkpoint series, we discuss how scientists used AIM Biotech’s Avatar technology to study when, how, and which cells express the PD-L1 immune protein in breast cancer. PD-L1 expression promotes tumor growth by offering an invasive...